Welcome to the annual meeting for ImmunityBio, Inc. Our host for today's call is Rich Adcock. I will now turn the call over to your host. Mr. Adcock, you may begin, sir. Welcome to the 2026 Annual Meeting of Stockholders of ImmunityBio, Incorporated. We are holding a virtual Annual Meeting of Stockholders, which means the annual meeting takes place exclusively via internet webcast. This is the seventh year we are holding our annual meeting virtually. Stockholders attending the virtual meeting via internet webcast may vote their shares online in real time until the polls are closed. If you have already submitted a proxy to vote your shares, you do not need to submit an online ballot unless you want to change your vote. Before proceeding further, I'd like to note that many of the company's directors and officers are present virtually at this meeting. I would also like to introduce our independent registered public accounting firm, Deloitte & Touche LLP, and Benjamin J. Capps, a partner of Wilson Sonsini Goodrich & Rosati, who are present virtually today as well. We have asked Benjamin to act as a Secretary of the Meeting and record the minutes of this meeting. Also present virtually today is David Siddall of Broadridge Investor Communications Incorporated, who will serve as the Inspector of Elections for this annual meeting. This annual meeting is being held in accordance with the company's bylaws and Delaware law. During the formal meeting, we will address the matters described in the company's proxy statement dated April 29th, 2026. When we complete the balloting, an announcement will be made regarding the preliminary results. We will now proceed with the formal portion of this meeting. I have proof by affidavit that notice of this meeting has been duly given and that notice of internet availability of proxy materials was mailed on or about April 30th, 2026 to all stockholders of record on April 13, 2026, the record date for this annual meeting. The affidavit of mailing will be filed with the minutes of this meeting. The Inspector of Election has signed the Oath of Inspector of Election, which has been filed with the minutes of this meeting. The Inspector of Election has advised me that we have present in person and by proxy a sufficient number of shares to constitute a quorum on all matters being presented at the meeting, so the meeting is duly constituted. For purposes of this annual meeting, we will vote by proxy and by our online voting polls. For all proposals to be voted upon at this annual meeting, each holder of our common stock is entitled to one vote for each share of common stock held of record at the close of business on the record date. If you have turned in a proxy and do not intend to change your vote, it is not necessary for you to vote during this meeting because we will count your proxy. Those of you who did not turn in a proxy or wish to change your vote may vote virtually on the website used to access this meeting by following the instructions. After voting has been completed on all matters listed in the agenda, we will close the polls and the Inspector of Election will provide his preliminary report. The votes cast today will be counted in the final tally, along with the proxies previously received. The polls for each matter to be voted upon on this meeting are now open. The first order of business is the election of nine directors to serve until our 2027 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or his or her early retirement, resignation, disqualification, removal, or death. This item is discussed on page seven of the proxy statement. The company's Board of Directors presently has nine members, each with a one-year term. At each annual meeting, the terms of our nine incumbent directors expire and all members of our Board of Directors stand for election. As indicated in the proxy statement, the Board of Directors has nominated Dr. Patrick Soon-Shiong, Cheryl L. Cohen, Michael D. Blaszyk. General Wesley Clark, Dr. Linda Maxwell, Christobel Selecky, Dr. Barry Simon, Bruce Wendel, and myself, Richard Adcock, all of whom are current directors as nominees for re-election to the Board of Directors at this annual meeting to serve until our 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The company's bylaws require that a stockholder wishing to nominate a director candidate provide advance notice to the company of the stockholder's intent. No such notice was received. I declare the nominations for the directors closed. The Board of Directors recommends a vote for the election of each of the nine nominees to the Board of Directors. Those of you who are voting online during the meeting should now mark your online ballots on proposal number one to indicate how you are voting. The next order of business is the ratification of the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. This item is discussed on page 52 of the proxy statement. The audit committee of the Board of Directors selects the company's independent registered public accounting firm annually. The audit committee has selected Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. Stockholder ratification of the selection of Deloitte & Touche LLP is not required by the company's amended and restated bylaws or other applicable legal requirements. The audit committee is submitting the selection of Deloitte & Touche LLP to our stockholders because we value our stockholders' view on our independent registered public accounting firm and as a matter of good corporate governance. As noted in the proxy statement, stockholders may ask Deloitte & Touche questions at this meeting, no questions were submitted. The Board of Directors recommends a vote for the ratification of the selection of Deloitte & Touche LLP as ImmunityBio's independent registered public accounting firm for the fiscal year ending December 31st, 2026. Those of you who are voting online during the meeting should now mark your online ballots on Proposal 2 to indicate how you are voting. If you are voting today, you must submit your votes at this time in order for them to be counted by the Inspector of Election. The Inspector of Election will not accept proxies, ballots or votes or any changes or revocations submitted after the closing of the polls. The polls for each matter to be voted upon at this annual meeting are now closed. No additional ballots, proxies or votes and changes or revocations will be accepted. The Inspector of Election has delivered a preliminary report of voting results, which shows Dr. Patrick Soon-Shiong, Cheryl L. Cohen, Michael D. Blaszyk, General Wesley Clark, Dr. Linda Maxwell, Christobel Selecky, Dr. Barry Simon, Bruce Wendel, and I, Richard Adcock, have been elected as the directors to serve until the 2027 Annual Meeting of Stockholders and until their respective successor are duly elected and qualified, or until their earlier retirement, resignation, disqualification, removal, or death and the selection of Deloitte & Touche LLP as ImmunityBio's independent registered public accounting firm for the fiscal year ending December 31st, 2026, has been ratified. We will file the final report of the Inspector of Election with the records of this meeting. We plan to report the results of the voting on Form 8-K to be filed with the SEC within four business days of this meeting. There being no further business to come before this meeting, this Annual Meeting of Stockholders is now adjourned. Thank you for your attendance at today's meeting and your interest you've shown in our company and your ongoing support. This now concludes the meeting. Thank you for joining, have a pleasant day.